Clinical significance of epithelial–mesenchymal transition-related markers expression in the micrometastatic sentinel lymph node of NSCLC
A. Lafuente-Sanchis,A. Olmo,J. Carretero,J. Alcacer Fernandez-Coronado,M. Estors-Guerrero,N. J. Martínez-Hernández,A. Cremades,A. Zúñiga,J. Alcacer,R. Farras,M. Cuenca,J. M. Galbis-Caravajal
DOI: https://doi.org/10.1007/s12094-019-02138-3
2019-05-28
Abstract:<h3>Objectives</h3><p>Metastatic lymph node affectation is the main prognostic factor in localised lung cancer. However, the pathological study of lymph nodes reveals tumour relapse for 20% of patients after oncological curative surgery. Recently, EMT (epithelial-mesenchymal transition) has been established as one of the main factors related to lymphatic dissemination and metastasis. This study evaluated the prognostic value of EMT-related gene expression in micrometastatic sentinel lymph nodes (SLN) of non-small cell lung cancer (NSCLC) patients.</p><h3>Methods</h3><p>The presence of genes <em>CDH1, CDH2, VIM, TWIST1, SNAI1, SNAI2, ZEB1,</em> and <em>ZEB2</em> in mRNA was analysed in tumours and in the SLN of NSCLC patients for whom surgery was planned for treatment. The significant association between the expression level of EMT-related markers and patients' clinicopathological characteristics and relapse was assessed.</p><h3>Results</h3><p>Of the 96 patients, 56 (58.33%) presented molecular micrometastasis in SLN, which showed higher <em>CDH1</em>, <em>CDH2,</em> and <em>VIM</em> expressions than non-micrometastatic ones. An association linking a low <em>CDH1/CDH2</em> ratio in SLN with molecular micrometastasis, adenocarcinoma, and non-smoking patients was found. The multivariate Cox regression analysis proved the prognostic accuracy of the <em>CDH1</em>/<em>CDH2</em> ratio in SLN.</p><h3>Conclusions</h3><p>The molecular EMT status of SLN could be used as an independent prognosis predictor in early stage NSLCL patients, and as a new tool to better stratify and predict patient outcomes.</p>
oncology